Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
IRRAS AB specializes in innovative medical devices for neurocritical care, particularly focusing on the management of intracranial pressure with its flagship product, the IRRAflow system. The company operates primarily in Europe and North America, leveraging its unique technology to provide continuous drainage and monitoring of cerebrospinal fluid, which differentiates it from traditional methods.
IRRAS generates revenue through the sale of its proprietary IRRAflow system and associated consumables, which are critical for neurocritical care procedures. The company benefits from a recurring revenue model as consumables are required for each use of the system, providing a steady income stream. Its competitive advantage lies in its patented technology that allows for continuous monitoring and drainage, reducing the risk of complications associated with traditional methods.
Regulatory approvals for new products or indications
Adoption rates of the IRRAflow system in hospitals
Partnerships or collaborations with larger medical device companies
Changes in reimbursement policies for neurocritical care procedures
Regulatory changes affecting medical device approvals and market access
Technological advancements by competitors that could render IRRAS's products less competitive
Emergence of alternative technologies for intracranial pressure management
Aggressive pricing strategies from larger competitors in the medical device space
Negative operating cash flow impacting liquidity and ability to fund operations
Dependence on external funding for R&D and operational expenses
moderate - The demand for medical devices is somewhat insulated from economic cycles, but hospital budgets and capital expenditures can be affected by broader economic conditions.
Interest rates impact the company's cost of capital for financing growth initiatives and R&D investments. Higher rates may constrain expansion plans and affect valuation multiples.
minimal - The company has a low debt-to-equity ratio, indicating limited reliance on external financing.
growth - The innovative nature of the product and high revenue growth potential attract growth-focused investors.
high - The stock has shown significant price fluctuations, evidenced by a 61.7% decline over the past year.